Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder-Reference-Cited by-同舟云学术

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Published:2021-04-01 Issue:3 Volume:31 Page:214-226
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Nasser Azmi¹,Kosheleff Alisa R.¹,Hull Joseph T.¹,Liranso Tesfaye¹,Qin Peibing¹,Busse Gregory D.¹,O'Neal Welton¹,Fava Maurizio²,Faraone Stephen V.³,Rubin Jonathan¹

Affiliation:

1. Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA.

2. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.

3. Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York, USA.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology, and Child Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/cap.2020.0148

Reference52 articles.

1. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use

2. Age-Dependent Decline of Symptoms of Attention Deficit Hyperactivity Disorder: Impact of Remission Definition and Symptom Type

3. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention

4. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents;Expert Review of Neurotherapeutics;2024-03-19

2. Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree^®): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder;Brain and Behavior;2023-02-27

3. Adjuvant Therapy for Attention in Children with ADHD Using Game-Type Digital Therapy;International Journal of Environmental Research and Public Health;2022-11-14

4. A Paradigm for Targeting Functional Impairment as an Outcome in Attention-Deficit/Hyperactivity Disorder;Brain Sciences;2022-07-31

5. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder;CNS Drugs;2022-07-27